ACE2 News and Research

RSS

British and South African SARS-CoV-2 variants show some resistance to neutralizing antibodies

Researchers in France report impaired neutralization of two new SARS-CoV-2 variants by antibodies induced by vaccination or natural infection.

16 Feb 2021

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

A new preprint research paper posted to the bioRxiv server provides a greater understanding of the aspect of humoral immunity against the virus – the plasma cells that pour out a flood of specific antibodies targeting various epitopes on the pathogen.

16 Feb 2021

Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness

A new preprint research paper posted to the bioRxiv* server shows that these mutations disrupt inhibition by neutralizing antibodies, both natural and therapeutic.

16 Feb 2021

How SARS-CoV-2 enters the central nervous system

The central nervous system (CNS) is highly protected in the human body. Yet, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) invades the CNS, causing profound clinical complications. How is the CNS involved in a respiratory virus infection?

15 Feb 2021

SARS-CoV-2 South Africa and Brazil variants show resistance to therapeutic antibodies

Scientists from Germany have determined the efficacy of currently used therapeutics in treating newer variants of SARS-CoV-2, including the UK, South Africa, and Brazil variants. Their findings reveal that both B.1.351 and B.1.1.248 variants are able to escape humoral immune responses induced by therapeutic antibodies, vaccinations, or natural SARS-CoV-2 infection.

15 Feb 2021

RIG-1-like receptors may play dominant role in suppressing SARS-CoV-2 infection

A new study by researchers at the University of Connecticut Health Center, USA, reports the crucial nature of the pathogen pattern recognition receptor (PRRs), especially the two RLRs, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), in triggering host cell immune responses within the cell. The RLRs are viral RNA sensors.

15 Feb 2021

Researchers study host and viral transcriptomes in tandem to shed light on SARS-CoV-2 infection

In a new study, researchers discuss the use of simultaneous sequencing of both human and viral genes to better understand SARS-CoV-2's infection pathway.

15 Feb 2021

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

A new preprint research paper posted to the bioRxiv server demonstrates the potential of using the pre-existing protective responses to produce a broad-spectrum neutralizing response against not just SARS-CoV-2 but other future pathogens.

14 Feb 2021

New mouse model of SARS-CoV-2 infection reflects features of human infection

Now, a new preprint research paper posted to the bioRxiv server reports the development of a modified mouse model that allows productive SARS-CoV-2 infection of the mouse lungs, as well as the exploration of type I and III interferon responses in this condition.

14 Feb 2021

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

Scientists demonstrate how glue points and sequence alignment information can flag residue SARS-CoV-2 variants

Researchers in the U.S. have demonstrated how dominant energetic landscape mappings or glue points, along with sequence alignment information can potentially identify key residue mutations and spike protein deletions tied with emerging variants.

12 Feb 2021

Researchers identify protein sequences involved in SARS-CoV-2 infection

In the early days of the COVID-19 pandemic, it was established that SARS-CoV-2 infects cells by binding to the human protein ACE2, which plays a role in regulating blood pressure.

12 Feb 2021

Statins shown to reduce COVID-19 severity and lower mortality

Much attention has been focused on ways to reduce the deadly exaggeration of normal inflammatory reactions to this pathogen. A new research paper posted to the medRxiv* preprint server describes the alleviation of hyper-inflammatory phenomena following the administration of statins, drugs more widely known for their use in reducing blood cholesterol levels, to patients with COVID-19.

11 Feb 2021

Brain pericytes serve as a potential hub for SARS-CoV-2 infection

A team of scientists from the United States has recently conducted a study using pericyte-like cell-containing brain cortical organoids as an experimental model to investigate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the central nervous system.

11 Feb 2021

Higher proportion of male children develop COVID-19-related Multisystem Inflammatory Syndrome, finds study

Previous studies about COVID-19 have shown that the illness is often more severe in men than women. However, there is limited data available for the pediatric population. Though children and adolescents are at a lower risk of developing severe illness, some may experience severe symptoms. In some cases, children develop complications, including the multisystem inflammatory syndrome in children (MIS-C). Researchers report that a higher percentage of male children developed MIS-C and died.

11 Feb 2021

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Feb 2021

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Researchers at the Polish Academy of Sciences in Warsaw have identified a substrain of the recently emerged B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may confer resistance to antibody neutralization.

10 Feb 2021

Study shows local topological free energy as determinant of SARS-CoV-2 spike stability

A recent study conducted by US scientists has demonstrated that the distribution of local topological free energy along the spike protein domains of SARS-CoV-2 is associated with their activity in protein rearrangement.

10 Feb 2021

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Researchers highlight the potential causes of some COVID-19 symptoms. Early in the pandemic, the hallmark symptoms of COVID-19 include cough, fever, and shortness of breath. As the pandemic has evolved, more symptoms have emerged, such as loss of smell and taste, headache, intestinal issues, and abdominal pains.

10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

ACE2 News and Research

British and South African SARS-CoV-2 variants show some resistance to neutralizing antibodies

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness

How SARS-CoV-2 enters the central nervous system

SARS-CoV-2 South Africa and Brazil variants show resistance to therapeutic antibodies

RIG-1-like receptors may play dominant role in suppressing SARS-CoV-2 infection

Researchers study host and viral transcriptomes in tandem to shed light on SARS-CoV-2 infection

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

New mouse model of SARS-CoV-2 infection reflects features of human infection

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Scientists demonstrate how glue points and sequence alignment information can flag residue SARS-CoV-2 variants

Researchers identify protein sequences involved in SARS-CoV-2 infection

Statins shown to reduce COVID-19 severity and lower mortality

Brain pericytes serve as a potential hub for SARS-CoV-2 infection

Higher proportion of male children develop COVID-19-related Multisystem Inflammatory Syndrome, finds study

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Study shows local topological free energy as determinant of SARS-CoV-2 spike stability

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News